CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02215161
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:53.388355+00:00
- Published At
- 2018-06-26T00:00:00+00:00
- Record Updated At
- 2018-06-26
- Results Posted At
- 2018-06-26
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Castration Levels of Testosterone", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma in the Soft Tissue", "Prostate Carcinoma Metastatic in the Bone", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-06-26"- protocolSection.identificationModule.nctId
"NCT02215161"- protocolSection.identificationModule.officialTitle
"Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-06-26"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.